Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial

BACKGROUND: Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE). The contribution of ticagrelor, a P2Y12 antagonist and an adenosine enhancer, on blood viscosity (BV) and BV-dependent MBF i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenson, Robert S., Chen, Qinzhong, Najera, Sherwin D., Krishnan, Prakash, Lee, Martin L., Cho, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556022/
https://www.ncbi.nlm.nih.gov/pubmed/31174526
http://dx.doi.org/10.1186/s12933-019-0882-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6556022/
https://www.ncbi.nlm.nih.gov/pubmed/31174526
http://dx.doi.org/10.1186/s12933-019-0882-5

Ejemplares similares